These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9369221)
1. Molecular analysis of the interaction between HPV type 16 E6 and human E6-associated protein. Daniels PR; Sanders CM; Coulson P; Maitland NJ FEBS Lett; 1997 Oct; 416(1):6-10. PubMed ID: 9369221 [TBL] [Abstract][Full Text] [Related]
2. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities. Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343 [TBL] [Abstract][Full Text] [Related]
3. Characterization of the interactions of human papillomavirus type 16 E6 with p53 and E6-associated protein in insect and human cells. Daniels PR; Sanders CM; Maitland NJ J Gen Virol; 1998 Mar; 79 ( Pt 3)():489-99. PubMed ID: 9519827 [TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652 [TBL] [Abstract][Full Text] [Related]
5. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. Talis AL; Huibregtse JM; Howley PM J Biol Chem; 1998 Mar; 273(11):6439-45. PubMed ID: 9497376 [TBL] [Abstract][Full Text] [Related]
6. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding. Cho Y; Cho C; Joung O; Lee K; Park S; Yoon D Antiviral Res; 2000 Sep; 47(3):199-206. PubMed ID: 10974372 [TBL] [Abstract][Full Text] [Related]
7. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. Li X; Coffino P J Virol; 1996 Jul; 70(7):4509-16. PubMed ID: 8676476 [TBL] [Abstract][Full Text] [Related]
8. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity. Drews CM; Brimer N; Vande Pol SB PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989 [TBL] [Abstract][Full Text] [Related]
9. Defining the minimal requirements for papilloma viral E6-mediated inhibition of human p53 activity in fission yeast. Waddell S; Jenkins JR Oncogene; 1998 Apr; 16(13):1759-65. PubMed ID: 9582024 [TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6. Gardiol D; Banks L J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244 [TBL] [Abstract][Full Text] [Related]
11. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Scheffner M; Huibregtse JM; Vierstra RD; Howley PM Cell; 1993 Nov; 75(3):495-505. PubMed ID: 8221889 [TBL] [Abstract][Full Text] [Related]
12. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Srivenugopal KS; Ali-Osman F Oncogene; 2002 Aug; 21(38):5940-5. PubMed ID: 12185595 [TBL] [Abstract][Full Text] [Related]
13. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Crook T; Tidy JA; Vousden KH Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399 [TBL] [Abstract][Full Text] [Related]
14. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. Scheffner M; Takahashi T; Huibregtse JM; Minna JD; Howley PM J Virol; 1992 Aug; 66(8):5100-5. PubMed ID: 1321290 [TBL] [Abstract][Full Text] [Related]
15. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance. Brimer N; Vande Pol SB J Virol; 2014 Mar; 88(5):3027-30. PubMed ID: 24352452 [TBL] [Abstract][Full Text] [Related]
16. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Prabhu NS; Somasundaram K; Satyamoorthy K; Herlyn M; El-Deiry WS Int J Oncol; 1998 Jul; 13(1):5-9. PubMed ID: 9625796 [TBL] [Abstract][Full Text] [Related]
17. The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. Shally M; Alloul N; Jackman A; Muller M; Gissmann L; Sherman L Virus Res; 1996 Jun; 42(1-2):81-96. PubMed ID: 8806176 [TBL] [Abstract][Full Text] [Related]
18. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422 [TBL] [Abstract][Full Text] [Related]
19. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Cooper B; Schneider S; Bohl J; Jiang Yh; Beaudet A; Vande Pol S Virology; 2003 Feb; 306(1):87-99. PubMed ID: 12620801 [TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus E6 regulates the cytoskeleton dynamics of keratinocytes through targeted degradation of p53. Cooper B; Brimer N; Vande Pol SB J Virol; 2007 Nov; 81(22):12675-9. PubMed ID: 17804489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]